| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66c1b22707b0276e3078713a6ddcba91 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-036 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-07049
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1241 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-54 |
| filingDate |
2007-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_616052e647ba8ca4e0d9c32dcee8a4aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b53166e4b3146b8d1da31d4628c15a45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a8e370a808dc5f1f0e3ed4be5aea452
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2256b62dac4605d932a445c8c116e338 |
| publicationDate |
2009-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20090079938-A |
| titleOfInvention |
Telomerase reverse transcriptase fusion proteins, nucleotides encoding them, and uses thereof |
| abstract |
A polynucleotide is provided that encodes a TERT fusion protein comprising a telomerase reverse transcriptase (TERT) protein or a functional variant thereof fused to a substantial portion of a B subunit (LTB) of a heat labile toxin. TERT variants useful for the TERT-LTB fusion proteins of the invention include mutations that function to eliminate telomerase catalytic activity. The polynucleotides of the present invention can induce an immune response in mammals and, in a preferred embodiment, are stronger than the immune response induced by wild type TERT. TERT expression is generally associated with the progression of human carcinoma. The present invention provides compositions and methods for inducing or enhancing immunity to protein products expressed by TERT tumor-associated antigens, wherein abnormal TERT expression is associated with carcinoma or progression thereof. The present invention specifically provides adenovirus vectors and plasmid constructs having polynucleotides encoding TERT fusion proteins and TERT variants and describe their use in vaccines and pharmaceutical compositions for preventing and treating cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220020411-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160111362-A |
| priorityDate |
2006-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |